Background and Aims: Cholesterol efflux capacity (CEC) may be a more important risk marker than plasma HDL cholesterol levels. However, developing a standardized clinical laboratory test for measuring CEC would be extremely difficult because cell lines and pooled plasma are specific to each institution. The aim of this cross-sectional study was to identify phospholipid (PL) components of HDL, which are predictive of both decreased CEC and atherosclerosis severity, in order to develop novel standardized biomarkers as alternatives to CEC.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
185 / #173 Poster SAAG: REMOVING CHOLESTEROL: EFFLUX AND REVERSE CHOLESTEROL TRANSPORT 10-06-2020 12:00 PM - 1:00 PM
© 2020 Published by Elsevier Inc.